Table 1.
Baseline demographic characteristics of the study population (Number of subjects and percentages; mean values and standard deviations)
| Non- HANOD |
HANOD |
Total |
||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Total number of cases | 4309 | 199 | 4508 | |||
| Age (years) | ||||||
| Mean | 59 | 67 | 59 | |||
| SD | 18 | 18 | 18 | |||
| Sex | ||||||
| Female | 2836 | 66 | 125 | 63 | 2961 | 66 |
| Male | 1473 | 34 | 74 | 37 | 1547 | 34 |
| Race | ||||||
| White | 3606 | 84 | 168 | 84 | 3774 | 84 |
| Non-white | 703 | 16 | 31 | 16 | 734 | 16 |
| Patient type | ||||||
| Medical | 2517 | 58 | 138 | 69 | 2655 | 59 |
| Surgical | 1792 | 42 | 61 | 31 | 1853 | 41 |
| Deyo–Charlson Index | ||||||
| 0–3 | 1969 | 46 | 48 | 24 | 2017 | 45 |
| 4–6 | 1103 | 26 | 62 | 31 | 1165 | 26 |
| ≥7 | 1237 | 29 | 89 | 45 | 1326 | 29 |
| Recent surgery | 150 | 4 | 9 | 5 | 159 | 4 |
| Psychiatric primary diagnosis |
62 | 1·4 | 3 | 1·5 | 65 | 1·4 |
| Antipsychotic medications | 174 | 4 | 72 | 36 | 246 | 5 |
| Major depressive disorder history |
134 | 3 | 14 | 7 | 148 | 3 |
| 25(OH)D (ng/ml) | ||||||
| Mean | 22 | 19 | 22 | |||
| SD | 13 | 11 | 13 | |||
| Season of 25(OH)D draw | ||||||
| Autumn | 925 | 21 | 57 | 29 | 982 | 22 |
| Spring | 1096 | 25 | 38 | 19 | 1134 | 25 |
| Summer | 1035 | 24 | 61 | 31 | 1096 | 24 |
| Winter | 1253 | 29 | 43 | 22 | 1296 | 29 |
| Vitamin D supplemental use* |
501 | 12 | 36 | 18 | 537 | 12 |
| 90 d mortality | 284 | 7 | 47 | 24 | 331 | 7 |
HANOD, hospital-acquired new-onset delirium; 25(OH)D, 25-hydroxyvitamin D.
*
Vitamin D supplemental use refers to vitamin D supplementation in the year before hospitalisation.